/CLOV

Clover Health Investments Corp

CLOV

$4.82USD↑+2.34%+0.11 today

MARKET CAP

2.6B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$2

$6

AI Summary

Stalk

StalkMedium

CLOV has posted a decisive momentum breakout above the consolidation high with volume and EMAs aligned, but price is extended and RSI is overbought. In a Stage 2 advancing structure, medium-term bias remains bullish. We defer execution and await a shallow pullback into the rising 9- and 20-EMA near the $4.45–$4.60 support zone before participating in line with the Momentum + EPS strategy.

↑Q2 revenue $743.2M (+55.6% YoY) and EPS $0.05 beats estimates.
↑GAAP net income $28M vs $11M loss year-ago; adj. EBITDA +139%.
↓Forward P/E of 82 signals high valuation risk.

Full analysis →

Buying

8

institutions

Selling

5

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	35.11 M	183.96 M	+3.27 M	+228.3%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	4.38 M	22.94 M	+1.02 M	+288.4%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	2.81 M	14.71 M	+-594.10 K	+145.7%	0.02%
MM Millennium Management LLC Q2 2026	SELL	1.11 M	5.81 M	+-56.25 K	+183.3%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUY	1.07 M	5.60 M	+566.64 K	+533.1%	0.01%
AC Aqr Capital Management LLC Q2 2026	BUY	488.18 K	2.56 M	+382.99 K	+1281.8%	0.00%
VI Voloridge Investment Management, LLC Q2 2026	BUYNEW	482.49 K	2.53 M	+482.49 K	+0.0%	0.01%
JC Jpmorgan Chase & Co Q2 2026	SELL	296.37 K	1.67 M	+-40.73 K	+188.6%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	338.60 K	594.24 K	+169.30 K	+49.7%	0.00%
MG Man Group Plc Q2 2026	BUYNEW	63.35 K	331.96 K	+63.35 K	+0.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUY	28.17 K	147.61 K	+2.87 K	+231.4%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-116.25 K	-100.0%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	SELL	0.00	0.00	+-40.00 K	-100.0%	0.00%